1999•中国药理学报:英文版Requires access

Synergistic anticancer effects of tetrandrine combined with doxorubicin or vincristine in vitro

孙爱续, 叶祖光, 李春英, 薛宝云, 李兰芳, 曹秀芳, Yang Qing, 戴宝强

Open publisher page 0 citations

Abstract

目的:研究粉防己碱(Tet)和阿霉素(Dox)或长春新碱(Vin)联合用药在体外分别对人乳腺癌细胞MCF7及其抗Dox细胞MCF7/Dox或人口腔上皮样癌细胞KB及其抗Vin细胞KBV200的相互作用的性质.方法:MTT法测定Tet和Dox或Vin单独用药或联合用药的抗癌活性.抑制浓度的分数之和(SFIC)值及等效剂量分析方法(Isobologram)评价Tet和Dox或Vin联合用药的相互作用的性质.结果:Tet和Dox或Vin联合用药时分别以三种不同比例配伍,其SFIC值均小于1.由此联合用药得到的等效剂量曲线图形均为凹形.结论:Tet和Dox或Vin体外联合用药抗癌相互作用的性质为明显的增效作用

About this research paper

What this paper is about

目的:研究粉防己碱(Tet)和阿霉素(Dox)或长春新碱(Vin)联合用药在体外分别对人乳腺癌细胞MCF7及其抗Dox细胞MCF7/Dox或人口腔上皮样癌细胞KB及其抗Vin细胞KBV200的相互作用的性质.方法:MTT法测定Tet和Dox或Vin单独用药或联合用药的抗癌活性.抑制浓度的分数之和(SFIC)值及等效剂量分析方法(Isobologram)评价Tet和Dox或Vin联合用药的相互作用的性质.结果:Tet和Dox或Vin联合用药时分别以三种不同比例配伍,其SFIC值均小于1.由此联合用药得到的等效剂量曲线图形均为凹形.结论:Tet和Dox或Vin体外联合用药抗癌相互作用的性质为明显的增效作用

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

目的:研究粉防己碱(Tet)和阿霉素(Dox)或长春新碱(Vin)联合用药在体外分别对人乳腺癌细胞MCF7及其抗Dox细胞MCF7/Dox或人口腔上皮样癌细胞KB及其抗Vin细胞KBV200的相互作用的性质.方法:MTT法测定Tet和Dox或Vin单独用药或联合用药的抗癌活性.抑制浓度的分数之和(SFIC)值及等效剂量分析方法(Isobologram)评价Tet和Dox或Vin联合用药的相互作用的性质.结果:Tet和Dox或Vin联合用药时分别以三种不同比例配伍,其SFIC值均小于1.由此联合用药得到的等效剂量曲线图形均为凹形.结论:Tet和Dox或Vin体外联合用药抗癌相互作用的性质为明显的增效作用

Key concepts: Tetrandrine, Doxorubicin, Vincristine, In vitro, Pharmacology, Chemistry, Medicine, Chemotherapy

Related papers

Back to paper searchBrowse research topicsOriginal source
Synergistic anticancer effects of tetrandrine combined with doxorubicin or vincristine in vitro — Research Paper | ScholarLens